September 16-30, 2012
Open publication - For Past Issues
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Glenmark Pharmaceuticals initiates phase II study of GBR 500 for Ulcerative Colitis
The trial is part of a strategic global collaboration between Glenmark and Sanofi
US FDA approves new multiple sclerosis treatment Aubagio
Most common side effects of Aubagio experienced by patients in clinical trials include diarrhoea, abnormal liver tests, nausea and…
Panacea Biotec inks strategic alliance with Osmotica Pharmaceuticals
Both Panacea Biotec and Osmotica Pharmaceuticals would equally share risk, investment and profit
Sun Pharma ranks 38 in Forbes 100 innovative companies’ list
One of five Indian companies in the listing
India to draw blueprint to curb spurious and not-of-standard medicines soon
International consultation on developing blueprint to combat spurious drugs with use of technology
Ginkgo biloba extract does not prevent Alzheimer’s dementia
The randomised, double-blind trial took place over five years, involving 2,854 people in France who were 70 years old or over
Venus Remedies bags first patent from Canada for Vancoplus
Venus Remedies plans to launch the product in Canada in next two years
Aurobindo Pharma receives US FDA approval for amlodipine besylate and benazepril hydrochloride…
Products have been approved out of Aurobindo Pharma's Unit VII (SEZ) formulations facility in Hyderabad Aurobindo Pharma has…